Ovarian Cancer: is a cancer that ignites in the female organs that produce eggs (ovaries). Ovarian cancer frequently goes undetected until it has spread within the pelvis and belly. At this late stage, ovarian cancer is more severe to treat and can be fatal.
Our laboratory uses tools from pharmacology, genomics, and cell signaling to identify new precision anticancer therapeutic strategies. Under this broad heading, our work involves three key a...
Estrogen metabolism is the ability to favorably excrete potentially toxic estrogens through urine and sweat. Impaired estrogen metabolism is associated with Endometriosis and Polycystic Ovar...
A subset of women with ovarian cancer will present with an apparently isolated adnexal mass. Many of these women will have early stage ovarian cancer with a relatively good prognosis. Unfortu...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
The microbiome signatures in the context of gynecologic cancers (endometrial and ovarian) and the potential for their clinical use will be discussed. The use of microfluidic technologies to i...
Molecular analyses of cancer biology have tended to segregate between a focus on nucleic acids – DNA, RNA and their modifications – and a focus on proteins and protein function. P...
With over 265,000 new cases per year and over 50,000 deaths, breast and ovarian cancers represent a significant health burden in the USA. Prior work has demonstrated that CD4 helper T c...
DATE: April 26, 2018TIME: 8:00am PST, 11:00am EST Engineered T cells expressing a tumor antigen-specific receptor have revolutionized the field of cancer therap...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...
DATE: November 15, 2017TIME: 10:00AM PTInteractions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
There has been a great deal of renewed attention in immuno-oncology over the last decade. Therapies for cancer are being developed, approved, and administered that can either initiate,...
DATE: May 9th, 2017TIME: 10:00AM PDT, 1:00PM ETMyeloproliferative neoplasms including myelofibrosis (MF) are characterized by anemia, splenomegaly, bone marrow fibrosis and inflammatory...
As next generation sequencing has lowered the price of DNA sequencing orders of magnitude below what it cost to create the first consensus human genome, the sheer diversity of human sequence...
Launched in early 2015, the Precision Medicine Initiative (PMI) takes advantage of the progress made in genomic testing – progress largely driven by rapid advances in DNA sequencing tec...
The starting point for an interaction between a patient and a clinician is almost always a set of clinical facts (aka a phenotype). Phenotype-first medicine is the standard way in which the p...
DATE: November 4, 2016
TIME: 10:00am PT, 1:00pm ET
How do you develop clinically relevant biomarkers?
Systematic tumor profiling with multi-omics tools and rapid analytical...
Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways e...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Genetic testing has been an important component of medical care for decades but the breadth and impact of testing has been steadily increasing as medical knowledge increases, appreciation of ...
The reproducibility of animal studies is now critical to ensure that limited resources are used wisely and that efforts yield useable knowledge. At this time, IACUCs and other similar a...
DATE: January 15, 2016
TIME: 7am EST, 12pm UK, 1pm CET
With an increasing number of biomarkers and, often, limited availability of biopsy material, there is a growing need for multiplexed...
Our laboratory uses tools from pharmacology, genomics, and cell signaling to identify new precision anticancer therapeutic strategies. Under this broad heading, our work involves three key a...
Estrogen metabolism is the ability to favorably excrete potentially toxic estrogens through urine and sweat. Impaired estrogen metabolism is associated with Endometriosis and Polycystic Ovar...
A subset of women with ovarian cancer will present with an apparently isolated adnexal mass. Many of these women will have early stage ovarian cancer with a relatively good prognosis. Unfortu...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
The microbiome signatures in the context of gynecologic cancers (endometrial and ovarian) and the potential for their clinical use will be discussed. The use of microfluidic technologies to i...
Molecular analyses of cancer biology have tended to segregate between a focus on nucleic acids – DNA, RNA and their modifications – and a focus on proteins and protein function. P...
With over 265,000 new cases per year and over 50,000 deaths, breast and ovarian cancers represent a significant health burden in the USA. Prior work has demonstrated that CD4 helper T c...
DATE: April 26, 2018TIME: 8:00am PST, 11:00am EST Engineered T cells expressing a tumor antigen-specific receptor have revolutionized the field of cancer therap...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...
DATE: November 15, 2017TIME: 10:00AM PTInteractions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
There has been a great deal of renewed attention in immuno-oncology over the last decade. Therapies for cancer are being developed, approved, and administered that can either initiate,...
DATE: May 9th, 2017TIME: 10:00AM PDT, 1:00PM ETMyeloproliferative neoplasms including myelofibrosis (MF) are characterized by anemia, splenomegaly, bone marrow fibrosis and inflammatory...
As next generation sequencing has lowered the price of DNA sequencing orders of magnitude below what it cost to create the first consensus human genome, the sheer diversity of human sequence...
Launched in early 2015, the Precision Medicine Initiative (PMI) takes advantage of the progress made in genomic testing – progress largely driven by rapid advances in DNA sequencing tec...
The starting point for an interaction between a patient and a clinician is almost always a set of clinical facts (aka a phenotype). Phenotype-first medicine is the standard way in which the p...
DATE: November 4, 2016
TIME: 10:00am PT, 1:00pm ET
How do you develop clinically relevant biomarkers?
Systematic tumor profiling with multi-omics tools and rapid analytical...
Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways e...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Genetic testing has been an important component of medical care for decades but the breadth and impact of testing has been steadily increasing as medical knowledge increases, appreciation of ...
The reproducibility of animal studies is now critical to ensure that limited resources are used wisely and that efforts yield useable knowledge. At this time, IACUCs and other similar a...
DATE: January 15, 2016
TIME: 7am EST, 12pm UK, 1pm CET
With an increasing number of biomarkers and, often, limited availability of biopsy material, there is a growing need for multiplexed...
Follow
